For: | Zheng YF, Fu X, Wang XX, Sun XJ, He XD. Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients. World J Clin Cases 2021; 9(33): 10075-10087 [PMID: 34904077 DOI: 10.12998/wjcc.v9.i33.10075] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v9/i33/10075.htm |
Number | Citing Articles |
1 |
Chunyu Tian, Minghui Wang, Hancheng Liu, Jianping Liu, Mengze Xu, Lihui Ma. Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer. Irish Journal of Medical Science (1971 -) 2023; 192(3): 1041 doi: 10.1007/s11845-022-03093-9
|
2 |
Katsuhiko Nara, Ayumi Taguchi, Takehito Yamamoto, Tetsushi Tsuruga, Yuri Tojima, Yuichiro Miyamoto, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori, Tappei Takada, Hiroshi Suzuki, Yutaka Osuga. Efficacy of regional cooling + oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin. Supportive Care in Cancer 2023; 31(5) doi: 10.1007/s00520-023-07718-2
|
3 |
Ralph F. Mangusan, Irene Ekwede, Anaida Widell. CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era. AJN, American Journal of Nursing 2022; 122(12): 32 doi: 10.1097/01.NAJ.0000901848.07128.92
|
4 |
Rahul Ladwa, Gerald Fogarty, Peggy Chen, Gurpreet Grewal, Chris McCormack, Victoria Mar, Delphine Kerob, Kiarash Khosrotehrani. Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective. Cancers 2024; 16(14): 2526 doi: 10.3390/cancers16142526
|